¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2022-07-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2022-07-16
±³À°ÀÏÀÚ : 2022-07-16
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õ·ë  
±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò 
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼­¿ïÁöºÎȸ  
´ã´çÀÚ : Á¤ÇýÁ¤ ±³¼ö
¿¬¶ôó : 02-2260-7315  
À̸ÞÀÏ : humeong01@nmc.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ ȸ¿ø ÀÌ¿Ü´Â 50¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:05~14:25 Dupilumab vs JAK Inhibitor for atopic dermatitis  ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:25~14:45 Safer use of JAK inhibitor  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:45~15:05 Practical treatment approaches of chronic urticaria in Korea  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
Åä·Ð 07-16 ¶óº¥´õ·ë 15:05~15:15 Q&A  () 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:15~15:35 Treatment of nail dystrophy and ingrowing nail  ¿Àº´È£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:35~15:55 Finasteride vs dutasteride for androgenetic alopecia  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:55~16:15 Supportive and adjunctive treatment for hair loss  ÃÖÀ±Áø(¿¬¼¼º½ºûÇǺΰú) 
Åä·Ð 07-16 ¶óº¥´õ·ë 16:15~16:25 Q&A  () 
È޽Ġ07-16 ¶óº¥´õ·ë 16:25~16:50   () 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 16:50~17:10 Increasing the usefulness of patch test in allergic contact dermatitis  °íÁÖ¿¬(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 17:10~17:30 My experience of hypopigmenting agents including tranexamic acid in clinical practice  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 17:30~17:50 RF vs HIFU: basic steps for skin rejuvenation  Á¤¿î°æ(À¯¾ØÁ¤ÇǺΰú) 
Åä·Ð 07-16 ¶óº¥´õ·ë 17:50~18:00 Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2022-07-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ºÎ»ê±¤¿ª½ÃÀÇ»çȸ Á¦4±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤ : 2022-07-17
´ÙÀ½±Û ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ⸳ 10Áֳ⠱â³ä ½ÉÆ÷Áö¾ö : 2022-07-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20424 ¼­¿ï ´ëÇÑ»óºÎÀ§Àå°ü¡¤Ç︮ÄÚ¹ÚÅÍÇÐȸ Á¦ 30Â÷ ÇмúÁý´ãȸ : 2024-04-29 0 43 2024-04-16
20423 °æ±â (¿Â¶óÀÎ) 2024³â 1Â÷ ¼Ò¾Æ¼ö¸é¿¬±¸È¸ Áý´ãȸ : 2024-04-29 0 74 2024-04-16
20422 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°¡¿Í»ç³¢º´ÇÐȸ Çмú´ëȸ (Á¦18ȸ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿ò) : 2024-04-28 0 61 2024-04-16
20421 ¼­¿ï 2024³âµµ ´ëÇѽŰæ°úÇÐȸ ÅëÁõ ½Ç±â ¿öÅ©¼ó : 2024-04-28 0 57 2024-04-16
20420 ¼­¿ï ½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (2ÀÏÂ÷) : 2024-04-27 0 56 2024-04-16
20419 ¼­¿ï ´ëÇѺñ´¢»ý½Ä¿µ»óÀÇÇÐȸ Á¦21ȸ Á¤±âÇмú´ëȸ : 2024-04-27 0 43 2024-04-16
20418 ±¤ÁÖ ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_3rd day : 2024-04-27 0 39 2024-04-16
20417 ºÎ»ê ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(2ÀÏÂ÷) : 2024-04-27 0 45 2024-04-16
20416 ¼­¿ï 2024³â ´ëÇѳ»°úÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-27 0 52 2024-04-16
20415 ºÎ»ê 2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-04-27 0 24 2024-04-16
20414 ¼­¿ï 2024 Çѱ¹´ç´¢º´¿¹¹æ¿¬±¸(KDPS) Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-27 0 37 2024-04-16
20413 ¼­¿ï ½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (1ÀÏÂ÷) : 2024-04-26 0 2,546 2024-04-15
20412 ¼­¿ï ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-26 0 2,233 2024-04-15
20411 ±¤ÁÖ ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26 0 2,279 2024-04-15
20410 ºÎ»ê ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26 0 2,299 2024-04-15
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷